Cost-effectiveness analysis of adjuvant therapy with atezolizumab in Chinese patients with stage IB-IIIA resectable NSCLC after adjuvant chemotherapy

Cost-effectiveness analysis of adjuvant therapy with atezolizumab in Chinese patients with stage IB-IIIA resectable NSCLC after adjuvant chemotherapy

BackgroundAtezolizumab was first shown to significantly improve progression-free survival (PFS) after platinum-based chemotherapy in early-stage non-small cell lung cancer (NSCLC) in the IMpower010 Phase 3 trial. However, the cost-effectiveness and potential economic impact of atezolizumab treatment...

Full description

Bibliographic Details
Main Authors: Ping Chen, Qing Yang, Yinfeng Li, Xiaomei Jing, Jing Chen
Format: Article
Language:English
Published: Frontiers Media S.A. 2022-09-01
Series:Frontiers in Oncology
Subjects:
atezolizumab
non-small-cell lung cancer
cost-effectiveness
adjuvant therapy
China
Online Access:https://www.frontiersin.org/articles/10.3389/fonc.2022.894656/full

Internet

https://www.frontiersin.org/articles/10.3389/fonc.2022.894656/full

Similar Items